Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study

BACKGROUND: Angiogenesis is critical to colorectal cancer (CRC) growth and metastasis. Phase I/II studies have demonstrated the efficacy of nintedanib, a triple angiokinase inhibitor, in patients with metastatic CRC. This global, randomized, phase III study investigated the efficacy and safety of ni...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Cutsem, E, Yoshino, T, Lenz, H J, Lonardi, S, Falcone, A, Limón, M L, Saunders, M, Sobrero, A, Park, Y S, Ferreiro, R, Hong, Y S, Tomasek, J, Taniguchi, H, Ciardiello, F, Stoehr, J, Oum’Hamed, Z, Vlassak, S, Studeny, M, Argiles, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158765/
https://www.ncbi.nlm.nih.gov/pubmed/30010751
http://dx.doi.org/10.1093/annonc/mdy241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158765/
https://www.ncbi.nlm.nih.gov/pubmed/30010751
http://dx.doi.org/10.1093/annonc/mdy241

Ejemplares similares